Palonosetron+Aprepitant+Dexamethasone for moderately emetic chemotherapy induced nausea and voimiting-Phase II study
Phase 2
Completed
- Conditions
- ung cancer
- Registration Number
- JPRN-UMIN000004936
- Lead Sponsor
- iigata Lung Cancer Treatment Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 160
Inclusion Criteria
Not provided
Exclusion Criteria
1)MEC administration except Day 1. 2)Radiation therapy 3)Contraindication of Dexamethasone 4)Symptomatic brain meta 5)Hypersensitivity for Palonosetron, Aprepitant, Dexamethasone 6)Vomiting episode prior to chemotherapy with 24 hours
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Complete response rate in 1st course of chemotherapy
- Secondary Outcome Measures
Name Time Method Complete response rate in any course of chemotherapy Complete control rate Time to treatment failure QOL analysis Toxicity
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the antiemetic effects of palonosetron, aprepitant, and dexamethasone in chemotherapy-induced nausea and vomiting?
How does the combination of palonosetron, aprepitant, and dexamethasone compare to standard antiemetic regimens in patients undergoing moderately emetic chemotherapy for lung cancer?
Are there specific biomarkers that can predict patient response to the palonosetron-aprepitant-dexamethasone regimen in the context of chemotherapy-induced nausea and vomiting?
What are the known adverse events associated with palonosetron, aprepitant, and dexamethasone combination therapy, and what management strategies are recommended for these side effects in lung cancer patients?
What are the current trends in antiemetic combination therapies for chemotherapy-induced nausea and vomiting, and how does the palonosetron-aprepitant-dexamethasone regimen fit into this therapeutic landscape for lung cancer treatment?